BOISBRIAND, QUEBEC, CANADA – January 18, 2024 – Charles River Laboratories’ (NYSE:CRL) AccelLAB business (“AccelLAB” or the “Company”) was acquired by key members of the AccelLAB management team. The Company will now operate independently as a standalone preclinical CRO serving the medical device market.
AccelLAB is a leading North American preclinical CRO performing GLP and non-GLP studies of implantable Class III medical devices and biologics for clients in North America, Europe and Asia. The Company has specialized capabilities in intervention cardiology, orthopedics, dental medicine, ENT, regenerative medicine and more. The Company currently employs ~100 employees across its facilities in Boisbriand and Terrebonne, Quebec, Canada.
Louis-Georges Guy, PhD, Senior Director of Science at AccelLAB, said, “We are pleased to announce that AccelLAB is resuming its independent turnkey research activities on medical device safety and efficacy preclinical evaluation in Boisbriand, QC, Canada. More than ever, we’re ready to support our clients’ R&D programs with safety, efficacy and performance evaluation. We are excited to help our clients access to the medtech market with the same commitment to scientific excellence, client-centric appreciation, and an understanding of regulatory considerations.”
Fairmount Partners, a leading investment bank in the pharma services industry, served as the exclusive financial advisor to Charles River Laboratories.
About Charles River Laboratories
Charles River Laboratories provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories’ dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about its unique portfolio and breadth of services, visit www.criver.com.
About AccelLAB
AccelLAB is a leading North American preclinical CRO performing GLP and non-GLP studies of implantable Class III medical devices and biologics for clients in North America, Europe and Asia. The Company has specialized capabilities in intervention cardiology, orthopedics, dental medicine, spine, ENT, regenerative medicine and much more. The Company currently employs ~100 employees across its facilities in Boisbriand and Terrebonne, Quebec, Canada.
About Fairmount Partners
Fairmount Partners is an independent merger and acquisition advisory firm focused on emerging growth and middle-market companies. Fairmount helps its clients complete mergers and acquisitions, raise funds for growth, acquisitions and liquidity, and design and improve their corporate development strategies. Fairmount’s clients include successful entrepreneurs, private equity-sponsored enterprises and global public companies. Fairmount’s Healthcare group has completed 180 transactions for clients in 23 countries throughout North and South America, Europe, Asia and Australia. For additional information, please visit www.fairmountpartners.com.
Contact:
Neal McCarthy
Managing Director
neal.mccarthy@fairmountpartners.com
Cecilia Gleason, PhD
Director
Fairmount Partners 